By Moses Nosike
Nigeria’s pharmaceutical manufacturing capacity is expected to receive a boost with plans by Bloom Public Health and Centenary City to develop a Pharmaceutical and Biotech Park in Abuja to attract investment in local drug production and biotechnology.
The project, being developed through Bloom Pharmacity Limited, is designed to provide an integrated industrial environment for pharmaceutical manufacturers, biotechnology companies and healthcare supply-chain operators seeking to establish or expand production facilities in Nigeria.
The initiative comes amid growing calls for increased domestic pharmaceutical production as Nigeria seeks to reduce dependence on imported medicines and strengthen its healthcare supply-chain resilience.
Africa’s pharmaceutical market was valued at approximately $27.65 billion in 2024 and is projected to reach $36.96 billion by 2033, according to Grand View Research.
Nigeria’s pharmaceutical market, estimated at about $3.34 billion in 2026, is projected to grow annually by 9.5 per cent through 2033, according to Coherent Market Insights.
Despite the growth prospects, Nigeria remains substantially dependent on imported medicines and pharmaceutical inputs, making the expansion of local manufacturing an important component of efforts to strengthen medicine security.
The proposed park will occupy several hectares of master-planned industrial land within Centenary City, with serviced plots of approximately 5,000 square metres available to prospective manufacturers.
Its planned infrastructure includes internal road networks, power distribution, water supply, effluent and sewage treatment facilities, and gas reticulation.
Bloom Public Health will serve as the technical partner, providing support in Good Manufacturing Practice (GMP), quality management systems, facility layout planning and regulatory-readiness advisory.
The support is intended to help participating manufacturers meet applicable requirements of the National Agency for Food and Drug Administration and Control (NAFDAC), as well as relevant international standards, including World Health Organisation prequalification requirements where applicable.
Speaking on the initiative, the Chief Executive Officer of Bloom Public Health, Prof. Chimezie Anyakora, said the project was designed to strengthen Nigeria’s health security through sustainable local pharmaceutical manufacturing and position Abuja as a leading hub for pharmaceutical and biotechnology development.
He said the vision was to establish a well-planned pharmaceutical and biotechnology centre that would bring together the infrastructure, technical expertise and support services required to build a sustainable manufacturing ecosystem.
According to him, the park’s proximity to the Nnamdi Azikiwe International Airport, location within a Free Trade Zone and access to four universities offering pharmaceutical and life sciences programmes within a 30-mile radius give it strategic advantages.
Anyakora said the project would also provide technical support to manufacturers seeking to establish compliant production facilities, building on NAFDAC’s 5+5 policy.
The proposed industrial park is expected to incorporate cold-chain and warehousing logistics hubs, quality-control laboratories, regulatory liaison offices and commercial banking services to support manufacturers and other operators.
Its location within Centenary City’s Free Zone framework is also expected to provide eligible businesses with access to applicable tax, customs and other investment incentives, subject to relevant approvals and regulatory conditions.
The project partners said the integrated model was intended to address challenges associated with pharmaceutical manufacturing, including facility design, production processes, quality assurance, regulatory compliance, utilities, workforce capacity and supply-chain reliability.
They added that bringing manufacturers and supporting services together within a coordinated industrial zone would improve infrastructure efficiency and reduce duplication of investment.
The park is currently in its primary and secondary infrastructure rollout phase, with the onboarding of initial facilities targeted for the first quarter of 2027.
The development is expected to create investment opportunities for pharmaceutical manufacturers, biotechnology companies, institutional investors, infrastructure providers and specialised healthcare logistics operators.
However, the project’s success will depend on its ability to attract credible manufacturers, mobilise investment and support quality-assured production facilities capable of meeting local and international standards.
Bloom Pharmacity Limited has invited pharmaceutical manufacturers, biotechnology companies, infrastructure investors and healthcare logistics operators to engage with its project team.
Interested organisations can request the project prospectus, obtain information on plot specifications or arrange site visits through the project secretariat.

No comments yet. Start the conversation.